TK210 ELISA – universal serum protein biomarker for cancer screening, diagnosis, treatment response monitoring and early detection of relapse (UNIBIO)

Project Information

UNIBIO

Grant agreement ID: 697419

DOI 10.3030/697419

Closed project

EC signature date 15 September 2015

Start date 1 September 2015

End date 31 October 2015

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost € 71 429,00

EU contribution € 50 000,00

Coordinated by

AROCELL AB (PUBL)
Sweden

Objective

The UNIBIO project is a feasibility study for TK210 ELISA – a serum and plasma biomarker for cancer diagnosis and treatment response. Leveraging on the knowledge that cancer cells undergoing rapid growth produce and release into the blood abnormal amounts of protein called thymidine kinase (TK), AroCell has pre-validated a biomarker that quantifies the amount of TK protein directly in the serum in a blood sample. Current cell growth-related biomarkers are measured from tumour tissue, which limits their clinical utility. Recognizing a strong business opportunity, AroCell will propose TK210 ELISA as an easily-deployable and cost-efficient diagnostic and treatment-response test. The key need of clinicians and oncologists is the access to reliable biomarkers for the malignancy potential of cancer at diagnosis and effective monitoring of therapies. The test should make it possible to implement cost-efficient added information for diagnosis and follow-up. In the Phase 1 project, AroCell will perform a feasibility study verifying the clinical and economic viability of the clinical validation to be performed in the Phase 2 project. The EU added value of the project lies in the possibility to improve diagnostic accuracy using a minimally invasive diagnostic procedure based on the ELISA platform that is established within the EU Community.

Fields of science

• medical and health sciences › clinical medicine › oncology

Programme(s)

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.3. - Treating and managing disease

Topic(s)

• PHC-12-2015-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices

Call for proposal

H2020-SMEInst-2014-2015

See other projects for this call

Sub call

H2020-SMEINST-1-2015

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

AROCELL AB (PUBL)

• Net EU contribution: € 50 000,00
• Address: VIRDINGS ALLE 32 B ; 754 50 UPPSALA ; Sweden
• SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes:
  Region
  Östra Sverige › Östra Mellansverige › Uppsala län
• Region: Östra Sverige › Östra Mellansverige › Uppsala län
• Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Total cost: € 71 429,00